Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTIW59R)

DTT Name C-X-C chemokine receptor type 5 (CXCR5)
Synonyms Monocyte-derived receptor15; Monocyte-derived receptor 15; MDR15; MDR-15; Chemokine receptor CXCR5; CXCR-5; CXC-R5; CD185; Burkitt'S lymphoma receptor 1; Burkitt lymphoma receptor 1; BLR1
Gene Name CXCR5
DTT Type
Clinical trial target
 [1]
BioChemical Class
GPCR rhodopsin
UniProt ID
CXCR5_HUMAN
TTD ID
T09528
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MNYPLTLEMDLENLEDLFWELDRLDNYNDTSLVENHLCPATEGPLMASFKAVFVPVAYSL
IFLLGVIGNVLVLVILERHRQTRSSTETFLFHLAVADLLLVFILPFAVAEGSVGWVLGTF
LCKTVIALHKVNFYCSSLLLACIAVDRYLAIVHAVHAYRHRRLLSIHITCGTIWLVGFLL
ALPEILFAKVSQGHHNNSLPRCTFSQENQAETHAWFTSRFLYHVAGFLLPMLVMGWCYVG
VVHRLRQAQRRPQRQKAVRVAILVTSIFFLCWSPYHIVIFLDTLARLKAVDNTCKLNGSL
PVAITMCEFLGLAHCCLNPMLYTFAGVKFRSDLSRLLTKLGCTGPASLCQLFPSWRRSSL
SESENATSLTTF
Function
Involved in B-cell migration into B-cell follicles of spleen and Peyer patches but not into those of mesenteric or peripheral lymph nodes. May have a regulatory function in Burkitt lymphoma (BL) lymphomagenesis and/or B-cell differentiation. Cytokine receptor that binds to B-lymphocyte chemoattractant (BLC).
KEGG Pathway
Cytokine-cytokine receptor interaction (hsa04060 )
Viral protein interaction with cytokine and cytokine receptor (hsa04061 )
Chemokine signaling pathway (hsa04062 )
Reactome Pathway
G alpha (i) signalling events (R-HSA-418594 )
Chemokine receptors bind chemokines (R-HSA-380108 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-06835375 DMNIYPS Immune thrombocytopenic purpura 3B64.13 Phase 2 [2]
SAR113244 DMRIH0S Systemic lupus erythematosus 4A40.0 Phase 1 [1]
------------------------------------------------------------------------------------
1 Preclinical Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
JT08 DM8OAZ6 Solid tumour/cancer 2A00-2F9Z Preclinical [3]
------------------------------------------------------------------------------------

References

1 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
2 ClinicalTrials.gov (NCT05070845) AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA. U.S.National Institutes of Health.
3 Clinical pipeline report, company report or official report of Jyant Technologies.